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L E F T  M A I N  C O R O N A R Y  A R T E R Y  D I S E A S E
Left main (LM) coronary artery disease, arbitrarily defined as >50% diameter 
stenosis of the LM coronary artery, has long been a topic of intense diagnostic and 
therapeutic investigation, due to its poor prognosis. As the majority of the left ven-
tricular myocardium is supplied by the LM stem, any ischemic insult may lead to 
hemodynamic compromise, significant ventricular arrhythmias or death. Previous 
studies that randomized patients with LM disease to medical treatment or coronary 
artery bypass grafting (CABG) demonstrated a survival advantage with CABG in most 
patient groups, especially when significant (>75%) LM disease or left ventricular 
dysfunction was present. Conservative management resulted in overall 3-year survival 
of 60%-85%, but as low as 34% in high risk individuals.1-3 Contemporary medical 
treatment has undoubtedly evolved since that era, but nowadays comparative data 
with CABG are not available.
The decision to treat LM disease may be challenging in certain cases with equivocal 
stenosis. In these patients intravascular ultrasound (IVUS) can accurately measure LM 
diameters and minimal luminal area (MLA), and LM disease with MLA >6.0 mm2 can 
be safely managed conservatively.4 The use of fractional flow reserve (FFR) seems to 
be a more physiologic method to assess the hemodynamic impact of LM disease, with 
an FFR value >0.80 appropriate to safely defer LM disease intervention.5 Caution 
must be addressed to avoid cases with significant proximal left anterior descending 
and circumflex coronary artery stenosis.6
P E R C U T A N E O U S  C O R O N A R Y  I N T E R V E N T I O N  ( P C I )  
V S  C O R O N A R Y  A R T E R Y  B Y P A S S  G R A F T I N G  ( C A B G )
There are certain small subgroups of patients with LM disease, in whom percutane-
ous coronary intervention (PCI) may be more appropriate. These include: a) patients 
presenting with acute coronary syndromes due to LM occlusion and hemodynamic 
compromise, who may benefit from expeditious percutaneous treatment, b) poor 
surgical candidates, usually with multiple severe comorbidities and c) patients with LM 
disease, but with coronary circulation protected by previous patent grafts (protected 
LM disease).7
The decision to recommend PCI or CABG for significant LM disease should take 
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AbbreviAtions
CABG = coronary artery bypass grafting
DES = drug-eluting stent(s)
FFR = fractional flow reserve
IVUS = intravascular ultrasound
LM = left main (coronary artery)
MACCE = major adverse cardiac and 
cerebrovascular events
MLA = minimal luminal area
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into account several important factors, among which are the 
location of LM disease (ostial, shaft, distal bifurcation), the 
coronary artery disease complexity, the anticipated complex-
ity of PCI and the presence of diabetes. Ostial or shaft LM 
disease is less common (20%-40% of LM disease) and PCI is 
associated with a generally favorable outcome, with a 3-year 
survival of 95%.8
Two randomized trials,9,10 several observational studies 
and metaanalyses have examined the effect of PCI or CABG 
in LM disease. As expected, CABG compared to PCI, is as-
sociated with higher in-hospital major adverse cardiac and 
cerebrovascular events (MACCEs).
In the long term and in the total patient cohort analyzed, 
the composite endpoint of death/myocardial infarction/stroke 
is similar between PCI and CABG, however PCI is associated 
with a 2-fold higher rate of new revascularization (25.9% vs 
13.7% at 5 years).11 In experienced centers post PCI restenosis 
(usually after complex LM bifurcation PCI leading to ostial 
left circumflex restenosis) is dealt with repeat PCI,12 but in 
low volume centers repeat revascularization should probably 
be treated with CABG.
It is clear that as complexity of coronary artery disease in-
creases, the benefit of CABG vs PCI becomes more apparent. 
High risk patients who are more suitable for CABG vs PCI are 
those with high SYNTAX score ≥33, diabetics, patients with 
chronic total occlusions or other reasons for incomplete PCI 
revascularization, or those with poor left ventricular function. 
Patients with LM disease and SYNTAX scores 0-22 and 23-
32 have similar 5-year outcomes.11 In low risk patients, PCI 
may be a reasonable treatment strategy, with the following 
prerequisites: avoidance of adhoc PCI, thorough discussion 
with the cardiac team on the benefit/risk of each treatment, 
acceptance of the anticipated long term dual antiplatelet 
therapy and the use of drug-eluting stents (DES), preferably 
the second generation stents.13 Finally, comparing PCI (with 
use of DES) versus CABG in women with LM disease in the 
Women-Drug-Eluting stent for Left main coronary Artery dis-
ease Registry, there was an advantage of CABG in MACCEs 
(odds ratio 0.429, p=0.001), driven exclusively by target vessel 
revascularization (odds ratio 0.185, p<0.001), but there was no 
difference observed after PCI or CABG in death, myocardial 
infarction, and stroke at long-term follow-up.14
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